Browsing Tag
Boston Scientific
28 posts
Beckman Coulter names Cat Jennings president as Danaher Diagnostics targets steadier growth
Beckman Coulter Diagnostics has appointed former Boston Scientific executive Catherine Jennings as president, giving her responsibility for a laboratory platform processing more than one million tests every hour. The leadership change comes as parent Danaher's Diagnostics business returns to stronger underlying growth outside volatile respiratory testing.
Boston Scientific’s cyberattack knocks its 2026 outlook off course
Manufacturing, order fulfilment and shipping have been restored, but the medical-device group still cannot quantify the full financial damage and will reset expectations with third-quarter results.
Leadless pacemakers: How tiny implants inside the heart are challenging cardiac leads
Leadless pacemakers are moving beyond a niche alternative for selected patients. Abbott’s AVEIR DR can pace both the right atrium and right ventricle using two communicating intracardiac devices, while Medtronic is extending battery life and Boston Scientific is developing a wireless pacemaker-defibrillator system. The technology removes the chest pocket and transvenous leads that create important complications in conventional pacing, but retrieval, long-term device accumulation, patient selection and the limits of current pacing modes still stand between leadless systems and wholesale replacement of traditional pacemakers.
Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy
Boston Scientific lifted FY 2026 guidance and disclosed a $1.5B MiRus TAVR bet, but BSX trades near 52-week lows as softer Q3 growth guidance stings.
Catheter Precision (VTAK) rallies 122% on new patents and Flyte 1,000 user milestone
Catheter Precision (VTAK) rallies 122% as two new patents and Flyte hits 1,000 users boost pivot story. Going concern warning still shadows the rally.
Could THUNDERBOLT sharpen Penumbra’s stroke portfolio before the Boston Scientific deal closes?
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy and computer assisted clot removal.
Penumbra (NYSE: PEN) says STORM-PE 90-day data strengthens case for thrombectomy in pulmonary embolism
Penumbra’s new STORM-PE data showed stronger 90-day recovery in pulmonary embolism patients. Read what it means for growth, competition, and care.
Will Carisa Schultz’s appointment help Nuwellis manage its cash crunch and regain trust?
Nuwellis appoints Carisa Schultz as CFO amid stock volatility and strategic expansion. Learn what this leadership change means for investors and medtech peers.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Haemonetics (NYSE: HAE) acquires Vivasure Medical in €185m deal to expand vascular closure portfolio for structural heart procedures
Haemonetics acquires Vivasure Medical to expand its hospital closure portfolio with PerQseal Elite. Find out what this means for structural heart growth.